(Reuters) – India’s Bharat Biotech said on Saturday a booster dose of its COVID-19 vaccine Covaxin offered long-term protection from severe disease in a trial.
The company said a booster dose was given to trial participants six months after they received their second dose.
(Reporting by Rhea Binoy in Bengaluru; Editing by Toby Chopra)
